AMENDMENTS TO THE SPECIFICATION

Before line 1 of the specification, please insert the following new paragraph:

This application is a Divisional of co-pending Application No. 10/145,712, filed on May 16, 2002, which is a Continuation Application of No. 09/642,826 filed on August 22, 2000, which is a Continuation of Application No. 08/476,607 filed on June 7, 1995, now abandoned, which is a Continuation of Application No. 08/155,864 filed on November 23, 1993, now USP 5,545,403, which is a Continuation of Application No. 08/046,893 filed April 15, 1993, now abandoned, which is a Continuation of Application No. 07/943,143 filed on September 10, 1992, now abandoned, which is a Continuation of Application No. 07/777,730 filed on October 16, 1991, now abandoned, and for which priority is claimed under 35 U.S.C. § 120; and this application claims priority of Application No. 9022543.4 filed in Great Britain on October 17, 1990, under 35 U.S.C. § 119. The entire contents of which are hereby incorporated by reference.

IN THE TITLE OF THE INVENTION:

~~ANTIBODY PRODUCTION~~ A GLYCOSYLATED ANTIBODY

IN THE SPECIFICATION:

Please replace the paragraph beginning at the bottom of page 25 bridging page 26 of the specification with the following amended paragraph:

The dhfr- CHO line DUK-B11 ~~[Urlaub, G. and Chasin, L.A. 1980 Proc.Natl.Acad.Sci.USA 77 4216-4220]~~ was propagated in Iscoves MEM medium supplemented with 10% foetal bovine serum and 4μg each of hypoxanthine and thymidine (all Flow). After transfection, transformats were selected in the medium described above except that the hypoxanthine/thymidine were omitted and dialysed foetal bovine serum was used. In addition, G418 was included at 500μg/ml. To induce spontaneous amplification of sequences containing and flanking the dhfr gene, MTX was added to a concentration of 0.1μM.